Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertion Holdings, Inc. ownership update: Nantahala Capital Management, LLC and its managers Wilmot B. Harkey and Daniel Mack report shared beneficial ownership of 692,335 shares of Common Stock as of March 31, 2026. The filing states this equals 10.74% of the class based on 6,445,161 shares outstanding reported in the issuer's Form 10-K filed March 16, 2026. The Reporting Persons disclaim sole voting or dispositive power and report only shared voting and disposition powers over the reported shares. A fund advised by Nantahala, Blackwell Partners LLC - Series A, is identified as having the right to receive dividends or sale proceeds on more than 5% of the reported holdings.
Assertio Holdings, Inc. is asking stockholders to vote at its May 5, 2026 virtual annual meeting on electing six directors, expanding its 2014 Omnibus Incentive Plan share pool, approving executive pay on an advisory basis, and ratifying Grant Thornton LLP as auditor.
The proxy highlights 2025 results including $117.1 million in product sales, with Rolvedon contributing $68.2 million, a GAAP net loss of $30.4 million, and non-GAAP adjusted EBITDA of $22.7 million. It also details leadership changes, stock ownership guidelines, a clawback policy and say‑on‑pay alignment with stockholder feedback.
Assertio Holdings, Inc. reports its 2025 results and strategic refocus on oncology, led by ROLVEDON. Net product sales were $117.1 million in 2025 versus $120.8 million in 2024, with ROLVEDON contributing $68.2 million, reflecting its role as the lead product.
The company divested Assertio Therapeutics on May 9, 2025, transferring opioid‑related legal liabilities, and advanced integration of products under Assertio Specialty. Large distributor purchases in 2025 shifted ROLVEDON sales timing, with minimal net product sales expected in early 2026 before normalized volumes in the second quarter.
Assertio recorded a net loss from operations of $21.5 million and used $28.2 million of operating cash flow in 2025, ending the year with $63.4 million in cash, cash equivalents and short‑term investments. A 1‑for‑15 reverse stock split was effected on December 26, 2025, and the company highlights reliance on a few large distributors and single‑source manufacturers as key risks.
Assertio Holdings reported mixed 2025 results, with net product sales of $117.1 million slightly below 2024, but non-GAAP adjusted EBITDA improving to $22.7 million from $18.3 million. The company still posted a larger GAAP net loss of $30.4 million, versus $21.6 million a year earlier.
Rolvedon remained the main growth driver with full-year net product sales of $68.2 million, while Sympazan rose and Indocin declined under generic pressure. For 2026, Assertio guides to net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million, reflecting expectations for stronger profitability despite ongoing portfolio transitions.
Schlessinger Sam reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings EVP and General Counsel Sam Schlessinger received new equity awards. On the reported date, he was granted 18,804 restricted stock units and 21,128 stock options, each RSU representing one share of common stock. One-third of both awards vest on each of the first three anniversaries of the grant date, subject to continued employment, and no cash consideration was paid for these grants.
Assertio Holdings, Inc. reported that EVP and CFO Ajay Patel acquired equity awards consisting of restricted stock units and stock options. He received 18,804 restricted stock units, each representing a right to receive one share of common stock, and 21,128 stock options.
One-third of both the restricted stock units and the stock options are scheduled to vest on each of the first three anniversaries of the March 2, 2026 grant date, assuming continued employment through each vesting date. The awards were granted for no cash consideration, so Patel did not pay to receive these derivative securities.
Assertio Holdings, Inc. reported that its President and COO, Paul Schwichtenberg, acquired equity awards in the form of restricted stock units and stock options. He received 24,820 restricted stock units, each representing a contingent right to one share of common stock, and 27,888 stock options. One-third of each award is scheduled to vest on each of the first three anniversaries of the March 2 grant date, contingent on continued employment. The awards were granted at no cost to him, as he did not pay any consideration for these derivative securities.
Reisenauer Mark L reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings CEO Mark L. Reisenauer received a grant of 26,667 stock options on March 2, 2026. These derivative securities were awarded at no cost to him and give the right to buy Assertio common stock.
One-third of the options will vest on each of the first three anniversaries of the grant date, assuming he remains employed through each vesting date. The reported amounts have been adjusted to reflect a 1-for-15 reverse stock split that occurred on December 26, 2025.
Assertio Holdings EVP and General Counsel Sam Schlessinger reported routine equity compensation activity. He exercised and settled 1,143 restricted stock units into the same number of common shares at $0.00 per share, then had 510 common shares withheld at $11.84 per share to cover taxes. After these transactions, he directly owned 14,738 shares of Assertio common stock.